Grifols, S.A. (NASDAQ:GRFS – Get Free Report)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $7.18, but opened at $6.85. Grifols shares last traded at $6.95, with a volume of 107,950 shares.
Grifols Trading Down 4.7 %
The stock has a market cap of $4.70 billion, a P/E ratio of 6.75 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 1.29. The firm’s 50 day moving average price is $7.41 and its 200-day moving average price is $7.28.
Grifols (NASDAQ:GRFS – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The company had revenue of $1.96 billion for the quarter. As a group, equities research analysts forecast that Grifols, S.A. will post 0.79 earnings per share for the current year.
Institutional Investors Weigh In On Grifols
Grifols Company Profile
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Grifols
- Roth IRA Calculator: Calculate Your Potential Returns
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is a SEC Filing?
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- NYSE Stocks Give Investors a Variety of Quality Options
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.